ArticleWorld journal of surgical oncology2025
The relationship between examined lymph nodes and oncological outcome of proximal gastrectomy for Siewert II/III adenocarcinoma of the esophagogastric junction.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe objective of this study was to summarize the oncological outcomes and long-term prognosis of patients with Siewert II/III adenocarcinoma of the esophagogastric junction (AEG) who underwent proximal gastrectomy (PG) at the China National Cancer Center (CNCC), with particular focus on the relationship between the number of examined lymph nodes (ELNs) and prognosis.
methodsWe retrospectively analyzed 242 patients with Siewert II/III AEG who underwent PG between 2017 and 2021 at the CNCC. Lymphadenectomy followed D1 + principles for early-stage and D2 for advanced-stage disease. Recurrence-free survival (RFS) and overall survival (OS) were assessed using Kaplan-Meier curves, and prognostic factors were identified through Cox regression. Restricted cubic spline (RCS) modeling was applied to explore the dose-response relationship between ELNs and OS.
resultsOf the 242 patients, 163 (67.4%) did not achieve textbook outcome with ≥ 30 ELNs (TO-30LN) and had significantly worse survival (OS: HR = 1.85, 95% CI: 1.08-3.18; RFS: HR = 1.88, 95% CI: 1.06-3.34; both P < .05). Multivariable analysis identified pN + status and Clavien-Dindo grade ≥ II complications as independent adverse prognostic factors. RCS analysis revealed a nonlinear association between ELN count and OS in cT2-3 disease, with an optimal range of 28-53 nodes, whereas no survival benefit was observed in cT4 disease.
conclusionFor Siewert II/III AEG following PG, achieving TO-30LN improved survival. RCS analysis revealed an optimal ELN threshold in cT2-3 patients, but no benefit in cT4, indicating limited suitability of PG for this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.